(S)-3-[4-(4-Carbamimidoyl-phenoxy)-butyrylamino]-N-[(S)-1-(1,1-dioxo-1λ⁶-thiomorpholine-4-carbonyl)-2-methyl-propyl]-succinamic acid | 160138-41-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-[4-(4-Carbamimidoyl-phenoxy)-butyrylamino]-N-[(S)-1-(1,1-dioxo-1λ⁶-thiomorpholine-4-carbonyl)-2-methyl-propyl]-succinamic acid
• 英文别名: (3S)-3-[4-(4-carbamimidoylphenoxy)butanoylamino]-4-[[(2S)-1-(1,1-dioxo-1,4-thiazinan-4-yl)-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
• CAS: 160138-41-0
• 化学式: C₂₄H₃₅N₅O₈S
• 分子量: 553.637
• InChiKey: FPOQHPVEVPIFME-RXVVDRJESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  217
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (S)-3-{4-[4-(Benzyloxycarbonylamino-imino-methyl)-phenoxy]-butyrylamino}-N-[(S)-1-(1,1-dioxo-1λ⁶-thiomorpholine-4-carbonyl)-2-methyl-propyl]-succinamic acid benzyl ester 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以73.8%的产率得到(S)-3-[4-(4-Carbamimidoyl-phenoxy)-butyrylamino]-N-[(S)-1-(1,1-dioxo-1λ⁶-thiomorpholine-4-carbonyl)-2-methyl-propyl]-succinamic acid
  参考文献：
  名称：

  Design, synthesis, and evaluation of orally active fibrinogen inhibitors

  摘要：

  Low molecular weight and orally active fibrinogen inhibitors are described. The compounds studied in this work were rationally designed based on a metabolic study of a peptidic fibrinogen inhibitor, 4-(4-amidinophenoxy)butanoylaspartylvaline (1, FK633), which led to the synthesis of a potent and orally active antiplatelet agent, 4-(4-amidinophenoxy)butanoylaspartylvalylthiomorpholine 1,1-dioxide (3 f, FR158999). (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00055-3

文献信息

• Bioorganic & Medicinal Chemistry Letters 1997, 7, 521-526
  作者：

  DOI：——

  日期：——
• Design, synthesis, and evaluation of orally active fibrinogen inhibitors
  作者：Akito Tanaka、Hiroyoshi Sakai、Takatoshi Ishikawa、Toshiaki Aoki、Yukio Motoyama、Hisashi Takasugi

  DOI：10.1016/s0960-894x(97)00055-3

  日期：1997.3

  Low molecular weight and orally active fibrinogen inhibitors are described. The compounds studied in this work were rationally designed based on a metabolic study of a peptidic fibrinogen inhibitor, 4-(4-amidinophenoxy)butanoylaspartylvaline (1, FK633), which led to the synthesis of a potent and orally active antiplatelet agent, 4-(4-amidinophenoxy)butanoylaspartylvalylthiomorpholine 1,1-dioxide (3 f, FR158999). (C) 1997 Elsevier Science Ltd.